21st Feb 2025 7:00 am |
RNS |
Director/PDMR Shareholding |
21st Feb 2025 7:00 am |
RNS |
Director/PDMR Shareholding |
21st Feb 2025 7:00 am |
RNS |
Director/PDMR Shareholding |
21st Feb 2025 7:00 am |
RNS |
Director/PDMR Shareholding |
21st Feb 2025 7:00 am |
RNS |
Director/PDMR Shareholding |
21st Feb 2025 7:00 am |
RNS |
Director/PDMR Shareholding |
20th Feb 2025 7:00 am |
RNS |
Nucala COPD submission accepted in China |
17th Feb 2025 7:00 am |
RNS |
GSK 5-in-1 meningitis vaccine approved by US FDA |
13th Feb 2025 3:30 pm |
RNS |
Director/PDMR Shareholding |
11th Feb 2025 3:30 pm |
RNS |
Director/PDMR Shareholding |
5th Feb 2025 7:00 am |
RNS |
Final Results |
3rd Feb 2025 4:48 pm |
RNS |
Total Voting Rights |
28th Jan 2025 7:05 am |
RNS |
Depemokimab dual filing in China and Japan |
28th Jan 2025 7:00 am |
RNS |
EMA accepts two submissions for depemokimab |
27th Jan 2025 7:05 am |
RNS |
EMA accept review Shingrix syringe presentation |
20th Jan 2025 7:00 am |
RNS |
Jemperli expanded approval in the EU |
16th Jan 2025 3:30 pm |
RNS |
Director/PDMR Shareholding |
15th Jan 2025 3:30 pm |
RNS |
Director/PDMR Shareholding |
14th Jan 2025 3:30 pm |
RNS |
Director/PDMR Shareholding |
13th Jan 2025 3:30 pm |
RNS |
Director/PDMR Shareholding |
13th Jan 2025 7:00 am |
RNS |
GSK enters agreement to acquire IDRx, Inc. |
10th Jan 2025 7:00 am |
RNS |
Shingrix fully liquid accepted for US FDA review |
7th Jan 2025 7:00 am |
RNS |
GSK ADC gets FDA breakthrough therapy designation |
3rd Jan 2025 7:00 am |
RNS |
GSK’s Nucala approved in China for use in CRSwNP |
2nd Jan 2025 3:00 pm |
RNS |
Total Voting Rights |
23rd Dec 2024 3:30 pm |
RNS |
Director/PDMR Shareholding |
20th Dec 2024 9:00 am |
RNS |
Block Listing Application |
20th Dec 2024 7:00 am |
RNS |
Headline results from phase III FIRST trial |
16th Dec 2024 7:11 am |
RNS |
Jemperli receives US FDA breakthrough designation |
16th Dec 2024 7:05 am |
RNS |
EMA grants PRIME Designation for GSK’227 |
16th Dec 2024 7:00 am |
RNS |
Jemperli receives positive CHMP opinion |
12th Dec 2024 3:30 pm |
RNS |
Director/PDMR Shareholding |
9th Dec 2024 6:29 pm |
RNS |
Overall survival data presented for Blenrep |
9th Dec 2024 7:05 am |
RNS |
Blenrep combination China filing acceptance |
9th Dec 2024 7:00 am |
RNS |
Nucala COPD submission accepted by US FDA |
5th Dec 2024 7:00 am |
RNS |
Zhifei China collaboration revised and extended |
2nd Dec 2024 3:30 pm |
RNS |
Director/PDMR Shareholding |
2nd Dec 2024 3:00 pm |
RNS |
Total Voting Rights |
27th Nov 2024 7:00 am |
RNS |
GSK liquid meningitis vaccine authorised in EU |
25th Nov 2024 7:00 am |
RNS |
Blenrep combinations accepted for US FDA review |